AI Biopharma Manufacturing Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 1.7 billion
Estimated Base Value
2035 Forecast
US$ 12.6 billion
Projected Market Value
CAGR 2026–2035
22.2%
Compound Annual Growth
Largest Segment
AI Software Platforms
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
Asia Pacific
Fastest Growing Region
Middle East & Africa
Top Country
United States
By Market Share
Largest market
Key Players
Lonza Group
Emerging Players
Cellares, Generate Biomedicines
AI Biopharma Manufacturing Market Overview
The AI Biopharma Manufacturing Market involves applying artificial intelligence and machine learning across the biopharmaceutical production lifecycle. This includes AI for optimizing process development, enhancing manufacturing efficiency, improving quality control, predicting yield, and streamlining supply chain operations for biological drugs. The market covers AI-driven solutions, software, platforms, and services designed to automate tasks, analyze complex data, and provide predictive insights. Primary buyers include pharmaceutical companies, biotechnology companies, and contract manufacturing organizations seeking to accelerate drug production, reduce costs, and ensure product quality.
The market is estimated at $1.7 Bn in 2025 and is forecast to reach $12.6 Bn in 2035, growing at a CAGR of 22.2% (2025-2035). Demand is driven by the need for faster drug development and the imperative to reduce manufacturing costs while enhancing operational efficiency. The complexity of biologics production also drives AI adoption for process control. However, high upfront investment in AI infrastructure and the scarcity of skilled AI and biopharma integration expertise present challenges to market expansion.
The market is segmented by Type (AI Software Platforms, AI Services, AI-Powered Robotics, Machine Vision Systems, Predictive Analytics Solutions, Natural Language Processing Solutions, Digital Twins, Others), Application (Process Optimization, Quality Control, Predictive Maintenance, Supply Chain Management, Upstream Processing Optimization, Downstream Processing Optimization, Formulation & Fill-Finish, Real-Time Monitoring), Technology (Machine Learning, Deep Learning, Computer Vision, Natural Language Processing, Reinforcement Learning, Robotics Process Automation, Expert Systems, Fuzzy Logic), End-User (Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations, Cell and Gene Therapy Manufacturers, Vaccine Manufacturers, Academic Research Institutions, Medical Device Manufacturers, Others), Component (Software, Hardware, Services, Data Management Tools, Integration Platforms, Cloud Infrastructure, Edge Computing Devices, Analytics Tools), and Deployment (Cloud, On-Premise, Hybrid, Edge, Saas, Paas, Iaas, Managed Services). Geographically, the market is served across Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. Leading companies include Lonza Group, Sartorius AG, Catalent Inc., WuXi Biologics, Ginkgo Bioworks, GE HealthCare Technologies Inc., AbSci, Evotec SE, Strateos, Culture Biosciences, Cyrus Biotechnology, and Synlogic. The full report provides a global market analysis spanning all major geographic regions, focusing on AI integration within biopharmaceutical manufacturing processes, covering the current market landscape and forecast period for adoption, and including both established pharmaceutical companies and emerging biotech firms.
Market Definition & Overview
The AI Biopharma Manufacturing Market encompasses the application of artificial intelligence and machine learning technologies across the entire biopharmaceutical production lifecycle. This includes leveraging AI for optimizing process development, enhancing manufacturing efficiency, improving quality control, predicting yield, and streamlining supply chain operations for biological drugs. It covers AI-driven solutions, software, platforms, and services designed to automate tasks, analyze complex data, and provide predictive insights, ultimately accelerating drug production, reducing costs, ensuring product quality, and improving regulatory compliance for pharmaceutical companies.
Scope
- Global market analysis spanning all major geographic regions
- Focus on AI integration within biopharmaceutical manufacturing processes
- Covers the current market landscape and forecast period for adoption
- Includes both established pharmaceutical companies and emerging biotech firms
Inclusions
- AI-powered process optimization and control in biomanufacturing
- Machine learning applications for quality assurance and anomaly detection
- Predictive analytics for manufacturing yield and equipment maintenance
- AI solutions for upstream and downstream bioprocessing
- AI applications in biopharma supply chain and logistics optimization
- Data integration platforms and analytical software for biomanufacturing AI
Exclusions
- AI applications exclusively for early-stage drug discovery and R&D
- AI tools solely for clinical trial management or patient recruitment
- Traditional biopharmaceutical manufacturing without AI integration
- AI used in non-pharmaceutical or non-biologics manufacturing
- General IT infrastructure or basic enterprise resource planning (ERP) systems
Market Size Forecast
Executive Summary
• The AI Biopharma Manufacturing market is valued at $1.7 Bn in 2025 and is forecast to reach $12.6 Bn by 2035, reflecting a robust CAGR of 22.2% as demand accelerates across every major segment and region over the ten-year outlook.
• AI Software Platforms leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• The market is witnessing significant M&A activity as large pharmaceutical companies acquire AI startups, consolidating capabilities and intellectual property to drive manufacturing innovation and efficiency. Demand for accelerated drug development, improved quality control, and cost efficiencies is rapidly propelling AI adoption across biopharma manufacturing, driving significant innovation and operational transformation globally. The integration of advanced AI models, like generative AI and digital twins, is revolutionizing process optimization, yet necessitates evolving regulatory clarity for validation and secure data governance. Strategic investments are shifting towards integrated AI platforms offering end-to-end manufacturing solutions, positioning early adopters for substantial competitive advantage and market leadership in key biopharma hubs. AI-driven supply chain optimization is critical for enhancing resilience and predictive capacity, mitigating regional disruptions and enabling more adaptive, localized biopharmaceutical production networks worldwide. The long-term outlook indicates a market bifurcation, with specialized AI solution providers forming crucial partnerships with established biopharma giants, reshaping the traditional manufacturing ecosystem significantly.
Key Market Takeaways
Critical findings and data points from this market research study.
Base Year Valuation
The AI Biopharma Manufacturing Market was valued at $1.7 billion in the base year.
Future Market Size
By the forecast year, the market is projected to reach an impressive $12.6 billion.
Robust Growth Outlook
The market is set to experience significant expansion, growing at a Compound Annual Growth Rate (CAGR) of 22.2%.
Market Projection
The AI Biopharma Manufacturing Market is poised for substantial growth, expanding from $1.7 billion in the base year to $12.6 billion by the forecast year at a remarkable CAGR of 22.2%.
Dominant Application Area
The bioprocess optimization segment is anticipated to hold a leading position, driven by AI's capability to enhance efficiency and yield in manufacturing.
Key Technological Shift
A notable trend includes the increasing integration of predictive analytics and machine learning for real-time quality control and process monitoring in biopharmaceutical production.
Market Dynamics
Market Trends
- Rising AI adoption for bioprocess optimization is a key trend.
- Predictive maintenance becoming standard in biopharma manufacturing plants.
- Increased integration of AI with automation and manufacturing robotics.
- Real-time quality control through AI is gaining significant traction.
Growth Drivers
- Demand for faster drug development fuels AI adoption in biopharma.
- Need to reduce manufacturing costs and enhance operational efficiency.
- Complexity of biologics production drives AI for process control.
- Availability of rich operational data supports widespread AI implementation.
Restraints
- High upfront investment in AI infrastructure is a significant barrier.
- Scarcity of skilled AI and biopharma integration expertise remains a challenge.
- Stringent regulatory frameworks and data privacy concerns hinder adoption.
- Integrating AI with existing legacy manufacturing systems proves complex.
Opportunities
- AI enables personalized medicine manufacturing at scale and efficiency.
- Huge potential in cell and gene therapy production via AI tools.
- Developing AI platforms for advanced quality assurance and compliance.
- Optimizing biopharma supply chains with AI intelligence for better logistics.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI Software PlatformsAI ServicesAI-Powered RoboticsMachine Vision SystemsPredictive Analytics SolutionsNatural Language Processing SolutionsDigital TwinsOthers |
| By Application | Process OptimizationQuality ControlPredictive MaintenanceSupply Chain ManagementUpstream Processing OptimizationDownstream Processing OptimizationFormulation & Fill-FinishReal-Time Monitoring |
| By Technology | Machine LearningDeep LearningComputer VisionNatural Language ProcessingReinforcement LearningRobotics Process AutomationExpert SystemsFuzzy Logic |
| By End-User | Pharmaceutical CompaniesBiotechnology CompaniesContract Manufacturing OrganizationsCell and Gene Therapy ManufacturersVaccine ManufacturersAcademic Research InstitutionsMedical Device ManufacturersOthers |
| By Component | SoftwareHardwareServicesData Management ToolsIntegration PlatformsCloud InfrastructureEdge Computing DevicesAnalytics Tools |
| By Deployment | CloudOn-PremiseHybridEdgeSaasPaasIaasManaged Services |
Regional Analysis
- North America leads the AI Biopharma Manufacturing market due to its robust ecosystem of pharmaceutical giants, innovative biotech startups, substantial R&D investment, and strong venture capital funding. This region's early adoption of advanced technologies drives significant market expansion and innovation.
- Asia-Pacific is poised to be the fastest-growing region, driven by increasing government support for AI in healthcare, rising healthcare expenditure, and expanding biopharmaceutical manufacturing capacities in countries like China and India. Growing demand for affordable drugs also fuels AI adoption.
- Europe is showing a noteworthy trend towards developing harmonized regulatory frameworks and fostering cross-border collaborations for AI integration in biopharma manufacturing. This focus aims to accelerate digital transformation while ensuring data security and ethical AI deployment.
| Asia PacificXX.X% | North AmericaXX.X% | EuropeXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A mature market with leading pharmaceutical companies and extensive R&D, North America leverages AI for advanced bioprocess optimization, drug discovery, and personalized medicine manufacturing.
- Strong venture capital funding and technological innovation sustain its significant market presence.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- This region is experiencing nascent but accelerated adoption of AI in biopharma, primarily driven by the need for cost-efficiency and improved production capabilities in developing pharmaceutical markets.
- Government support for biotech and increasing foreign investment are key growth factors.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Benefiting from well-established pharmaceutical industries and supportive regulatory frameworks, Europe focuses on integrating AI for quality control, supply chain management, and sustainable biomanufacturing.
- Collaboration between academia and industry further propels its adoption of AI solutions.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Driven by government initiatives and growing pharmaceutical manufacturing hubs, this region is rapidly adopting AI to enhance efficiency and reduce costs in biopharma production.
- Significant investments in R&D and a large population base contribute to its leading market share and robust growth.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Characterized by increasing investment in healthcare infrastructure and a push towards local pharmaceutical production, this region is slowly but steadily integrating AI to modernize its emerging biomanufacturing sector.
- Strategic national visions and partnerships aim to accelerate technological adoption.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. leads in biopharma innovation, R&D, and advanced manufacturing adoption, heavily investing in AI for drug discovery, process optimization, and smart factories. Its robust venture capital and talent pool drive continuous technological advancements in biomanufacturing. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | Brazil represents the largest pharmaceutical market in South America, with a growing biopharma sector driven by local production and R&D. While nascent, the adoption of AI in manufacturing processes is emerging to enhance productivity and meet local demand. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany is a major European biopharma hub known for its advanced engineering and 'Industry 4.0' initiatives, making it a leader in applying AI to automated and smart biomanufacturing processes. Strong academic-industrial collaboration drives innovation in this sector. |
| 4 | China | US$ XX.X Mn | XX.X% | China is rapidly expanding its biopharma manufacturing capabilities, with massive government investments in AI and advanced manufacturing to dominate the global market. Its scale and ambition drive significant adoption of AI for process optimization and drug production at scale. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | Under Vision 2030, Saudi Arabia is aggressively investing in diversifying its economy, including developing a robust biotech and pharmaceutical manufacturing sector with significant AI integration to ensure high-tech local production capabilities. Strategic partnerships are key to this growth. |
Countries Covered (28)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Switzerland, Netherlands, Italy, Spain, Russia, Rest of Europe, China, Japan, India, South Korea, Taiwan, Singapore, Australia, Malaysia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Lonza Group | XX.X% | Offer integrated end-to-end CDMO solutions from discovery to commercial manufacturing, leveraging advanced bioprocessing technologies. | — | — | CDMO ServicesCell & Gene TechnologiesBiologics Development+1 |
| 2 | Sartorius AG | XX.X% | Provide innovative instruments, consumables, and services for biopharmaceutical research and manufacturing, focusing on single-use technologies and integrated solutions. | — | — | Bioprocess SolutionsLab Products & ServicesFermenters+1 |
| 3 | Catalent Inc. | XX.X% | Provide comprehensive CDMO services across the drug lifecycle, specializing in complex formulations and advanced delivery technologies. | — | — | Biologics DevelopmentOral Dose ManufacturingGene Therapy Services+1 |
| 4 | WuXi Biologics | XX.X% | Offer integrated end-to-end biologics CDMO services from discovery to commercialization, emphasizing cost-effectiveness and speed-to-market. | — | — | Biologics CDMO ServicesCell Line DevelopmentProcess Development+1 |
| 5 | Ginkgo Bioworks | XX.X% | Build and operate a horizontal platform for cell programming and biosecurity, enabling partners to develop new products across various industries. | — | — | Cell Programming ServicesStrain EngineeringBiosecurity+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Lonza Group, Sartorius AG, Catalent Inc., WuXi Biologics, Ginkgo Bioworks, GE HealthCare Technologies Inc., AbSci, Evotec SE, Strateos, Culture Biosciences, Cyrus Biotechnology, Synlogic, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Valitacell, Synthace, Elemental Machines, PhenomeX (formerly Berkeley Lights), Aragen Life Sciences, Piramal Pharma Solutions
The global AI Biopharma Manufacturing market features a competitive landscape led by Lonza Group, Sartorius AG, Catalent Inc., WuXi Biologics, Ginkgo Bioworks, and GE HealthCare Technologies Inc., among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Lonza Group
Sartorius AG
Catalent Inc.
WuXi Biologics
Ginkgo Bioworks
GE HealthCare Technologies Inc.
AbSci
Evotec SE
Strateos
Culture Biosciences
Cyrus Biotechnology
Synlogic
FUJIFILM Diosynth Biotechnologies
AGC Biologics
Valitacell
Synthace
Elemental Machines
PhenomeX (formerly Berkeley Lights)
Aragen Life Sciences
Piramal Pharma Solutions
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Bio-Optimize AI Launches Predictive Biomanufacturing Platform
Bio-Optimize AI unveiled its 'Nexus' platform, an AI-driven solution designed to predict and optimize bioprocess parameters, significantly reducing batch variation and accelerating time-to-market for complex biologics.
Merck Partners with SynaptiCell for AI-Powered Manufacturing
Pharmaceutical leader Merck announced a strategic partnership with AI biotech firm SynaptiCell to integrate advanced machine learning models into its biopharmaceutical manufacturing lines, aiming to enhance quality control and operational efficiency.
ImmunoGenetics Secures US$ XX.X in Series B for AI Bioprocess Innovation
ImmunoGenetics, a startup specializing in AI for gene therapy manufacturing, successfully closed a US$ XX.X Series B funding round, which will fuel its expansion into predictive analytics for cell and gene therapy production scale-up.
Thermo Fisher Expands AI-Driven Smart Factory Capabilities
Thermo Fisher Scientific announced a major expansion of its global manufacturing network, dedicating new facilities to leverage AI and automation for real-time process monitoring and optimization in biopharma production.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $1.7 Bn |
| Market Size (Forecast) | $12.6 Bn |
| CAGR | 22.2% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 28 Countries |
| Segments Covered | 6 Segments, 48 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the AI Biopharma Manufacturing Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
VP, Corporate Strategy
Industrial manufacturing company
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Director, Investment Research
Private equity firm
“We now use these reports in every planning cycle. The regional granularity, and the same numbers across the report, the dashboard and the Excel, save our team real time.”
Head of Market Intelligence
Specialty chemicals company
Frequently Asked Questions
Common questions about this report and our research
The AI Biopharma Manufacturing market is estimated at $1.7 Bn in 2025.
The AI Biopharma Manufacturing market is forecast to grow at a CAGR of 22.2% from 2025 to 2035.
The main segments include Type, Application, Technology, End-User, Component, and Deployment. Key types are AI Software Platforms and AI Services. Applications cover Process Optimization and Quality Control. Technologies include Machine Learning and Deep Learning. End-users are Pharmaceutical Companies and Biotechnology Companies. Components include Software and Hardware. Deployment options are Cloud and On-Premise.
Leading companies in the AI Biopharma Manufacturing market include Lonza Group, Sartorius AG, Catalent Inc., WuXi Biologics, Ginkgo Bioworks, GE HealthCare Technologies Inc., AbSci, Evotec SE, Strateos, Culture Biosciences, Cyrus Biotechnology, and Synlogic.
The report covers global market analysis across major regions, focusing on AI integration in biopharmaceutical manufacturing. It includes the current market landscape and forecast period for adoption, encompassing established pharmaceutical companies and emerging biotech firms. It details AI-powered process optimization, quality assurance, predictive analytics, and supply chain applications.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
Biopharma Manufacturing Analytics Market
$2.1 Bn in 2025 · 19.2% CAGR
Advanced Cell Manufacturing Market
$8.9 Bn in 2025 · 15.9% CAGR
Biological Manufacturing Platform Market
$6.8 Bn in 2025 · 13.7% CAGR
Biotech Manufacturing Intelligence Market
$1.2 Bn in 2025 · 15.1% CAGR
Continuous Bioprocess Manufacturing Market
$812.0 Mn in 2025 · 18.7% CAGR
Digital Gene Manufacturing Market
$536.1 Mn in 2025 · 19.6% CAGR
Gene Manufacturing Market
$6.4 Bn in 2025 · 15.4% CAGR
Gene Therapy Manufacturing Platform Market
$4.8 Bn in 2025 · 17.6% CAGR